2023
Cost Consequence Analysis of ADMET 2
Mah E, Lanctôt K, Chen Q, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Mintzer J, Herrmann N. Cost Consequence Analysis of ADMET 2. American Journal Of Geriatric Psychiatry 2023, 31: s101. DOI: 10.1016/j.jagp.2022.12.147.Peer-Reviewed Original ResearchCost-consequence analysisHealth utilityPlacebo groupMethylphenidate treatmentEuroQol-five dimensions-five levelsAlzheimer's diseaseHealth statesCommon neuropsychiatric symptomsHealth utility scoresQuality of lifeBinary logistic regressionApathy treatmentBaseline demographicsDifferent time pointsPreference-based measuresMethylphenidate groupNeuropsychiatric symptomsClinical trialsEQ-5DSignificant apathyPatientsUtility scoresBetter health stateLogistic regressionMethylphenidate
2022
Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Perin J, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.066932.Peer-Reviewed Original ResearchHeterogeneity of responseAlzheimer's diseaseAD patientsBaseline anxietyPlacebo-controlled clinical trialApathetic AD patientsDaily Living ScaleCommon neuropsychiatric symptomsLow functional capacityLower functional capabilityNPI apathy scoreLower baseline anxietyAD medicationsDifference of changesNeuropsychiatric InventoryNeuropsychiatric symptomsApathetic patientsClinical trialsMonth visitTreatment outcomesEffect differencesSignificant apathyLiving ScaleApathy scoresFunctional capacity